Gender differences in paclitaxel-induced neuropathic pain behavior and analgesic response in rats

Boo-Young Hwang¹, Eun-Soo Kim¹, Chul-Hong Kim², Jae-Young Kwon¹, and Hae-Kyu Kim¹

Department of Anesthesia and Pain Medicine, ¹Pusan National University School of Medicine, ²Pusan National University School of Dentistry, Busan, Korea

Background: Females show greater sensitivity than males to several modalities of experimental pain. However, the gender differences in paclitaxel-induced neuropathic pain have not been studied. The current study examined the gender differences in neuropathic pain behavior and the effect of analgesics in a paclitaxel-induced neuropathic pain model in rats.

Methods: Neuropathic pain was induced by intraperitoneal injection of paclitaxel (2 mg/kg) on 4 alternate days in Sprague-Dawley rats of both genders. Mechanical allodynia was measured using a von Frey filament. The gender differences in analgesic responses were determined after administration of morphine (2 or 5 mg/kg), ketamine (2 or 5 mg/kg), or combined morphine (2 mg/kg) and ketamine (2 mg/kg).

Results: Paclitaxel induced mechanical allodynia, which began to manifest on day 4, peaked within 10 days, and plateaued for at least 2 months after the first paclitaxel injection. No gender difference in the manifestation of mechanical allodynia was observed. A 2 mg/kg dose of ketamine increased the mechanical threshold only in males. The 5 mg/kg dose of ketamine significantly increased the mechanical threshold in both genders. Morphine (2 and 5 mg/kg) dose-dependently increased the mechanical thresholds in both genders. The 2 mg/kg dose of ketamine enhanced the antinociceptive effect of 2 mg/kg morphine only in females.

Conclusions: No gender difference in paclitaxel-induced neuropathic pain or analgesic response to ketamine or morphine was observed in Sprague-Dawley rats. Low dose ketamine enhanced the analgesic effect of morphine on paclitaxel-induced mechanical allodynia but only in female rats. (Korean J Anesthesiol 2012; 62: 66-72)

Key Words: Ketamine, Mechanical allodynia, Morphine, Paclitaxel, Rat, Sex differences.
Introduction

Although cancer treatment with chemotherapeutic agents, such as taxanes, vinca alkaloids, and platinum complexes increases patient survival times, side effects may diminish quality of life. Paclitaxel (PAC) is a widely used chemotherapeutic drug for treating breast cancer, cervical cancer, ovarian cancer, non-small cell lung carcinomas, and Kaposi’s sarcoma. PAC binds to β-tubulin of microtubules, stabilizing microtubules and enhancing microtubule polymerization [1]. PAC induces a dose-limiting side effect, neuropathic pain, which is characterized by numbness, tingling, and burning. The mechanisms producing this neuropathic pain are not fully understood [2,3].

Many factors influence the incidence of chemotherapy-induced peripheral neuropathy, including patient age, dose intensity, cumulative dose, therapy duration, co-administration of other chemotherapeutic agents, and pre-existing conditions. Fifty-five percent of patients receiving a cumulative dose of 200 mg/m² PAC developed sensory disturbances compared to only 30% receiving 175 mg/m² [3].

Investigating chemotherapy-induced neuropathic pain is particularly difficult, because neuropathic pain may arise from multiple causes (chemotherapy, tumor effects, radiotherapy, surgical trauma, etc.). Animal models present a simpler situation. PAC-induced neuropathic pain (PINP) in rats is a commonly used model of chemotherapy-induced neuropathic pain. PAC-treated rats have pronounced mechanical allodynia, cold allodynia, and mechanical hyperalgesia but little or no heat hyperalgesia [2]. Nerve trauma models produce pronounced heat hyperalgesia. The observation that drug-induced neuropathic pain is related to an abnormality in mitochondria within sensory axons has been reported [4]. Flatters and Bennett [5] suggested that PAC induces degeneration or dysfunction of axonal microtubules without axonal degeneration or disruption of the axonal cytoskeleton. Massive axonal degeneration occurs in the nerve trauma model [6].

PAC is frequently used in female patients, but most animal experiments of PINP have been conducted with male rats or mice. Gender is a critical factor modulating the experience of pain. Males and females experience pain differently and respond differentially to specific classes of analgesic medications. A quantitative review of the literature regarding gender differences of experimental pain responses concluded that females show greater sensitivity to several modalities of experimental pain than males [7]. However, the relationship between pain behavior and gender differences in PINP has not been studied, and the gender differences in the clinical incidence of neuropathic pain after PAC administration have not been reported.

The objective of this study was to investigate the gender difference in pain behavior after a PAC injection in rats and to compare the effect of analgesics in this pain model.

Materials and Methods

Materials

Sprague-Dawley rats (n = 24), weighing 150 to 250 g at the start of the experiments, were used. Two rats per cage were housed under standard laboratory conditions with controlled room temperature (23°C) and a 12-hour light/dark cycle. This experimental protocol was approved by the Institutional Animal Care and Use Committee.

Animals were divided into two groups of males (n = 12) and females (n = 12). Each group was subdivided into a saline group (n = 4 each) and a PAC group (n = 8 each). Body weight was recorded on each experimental day.

Injection of PAC and development of neuropathic pain

Rats were placed in a Plexiglas box and anesthetized with 4% isoflurane and oxygen. After induction of anesthesia, rats were randomly injected intraperitoneally with 1 ml/kg saline or 1 ml/kg PAC (Taxol; Bristol-Myers-Squibb, New York, NY, USA, 2 mg/ml). PAC was diluted with saline to create a 2 mg/ml concentration that was injected intraperitoneally (2 mg/kg) on 4 alternate days (days 1, 3, 5, and 7). Body weight was recorded before the PAC or saline injections.

Behavioral testing

The behavioral test was conducted by an examiner who was blinded to the groups. The measured test was the foot withdrawal threshold in response to mechanical stimuli applied to the hind paws. Rats were placed in a Plexiglas chamber with a mesh floor. Before testing, rats were habituated to the testing environment for more than 15 minutes. Baseline measurements were taken prior to PAC administration. The plantar surface of the hind paw (sciatic nerve territory) was tested with a calibrated von Frey filament (3.65, 3.87, 4.10, 4.31, 4.52, 4.74, 4.92, and 5.16). The von Frey filament was applied perpendicularly to the most sensitive areas of the plantar surface at the center area of the paw or the base of the third or fourth toes with sufficient force to bend the filament slightly for 2−3 seconds. Abrupt withdrawal of the foot during stimulation or immediately after stimulus removal was considered a positive response.

The up-down method of Dixon [8] was used for testing the withdrawal threshold. The first stimulus was always the 4.31 filament. When there was a positive response, the next lower
filament was used, and when no response was observed, the next higher filament was applied. This testing pattern continued until responses to the sixth von Frey stimuli from the first change in response were measured. The responses were then converted into a 50% threshold value using the formula: 50% threshold = $10^{(X + kd)/10}$, where $X$ is the value of the final von Frey hair in log units, $k$ is the tabular value for the pattern of positive or negative responses, and $d$ is the mean difference between stimuli in log units (0.22). When negative or positive responses were still observed for the 3.84 or 5.18 filament, values of 0.3 or 15.0 g were assigned, respectively, by assuming a value of ± 0.5 for $k$. Testing was conducted on the day PAC was injected, and 2, 5, 7, 9, 11, 14, 18, 20, 22, 24, and 28 days after the fourth PAC injection.

Responses to analgesic drugs

The responses to analgesics were determined after intraperitoneal (i.p.) administration of 2 mg/kg ketamine, 5 mg/kg ketamine, 2 mg/kg morphine, 5 mg/kg morphine, and 2 mg/kg morphine plus 2 mg/kg ketamine at 32–60 days after PAC injection. Drugs were diluted with saline, and the concentration was adjusted to make an equal volume of 1 ml/kg. Mechanical thresholds of the right hind paws were measured before and 20 minutes after intraperitoneal injection of each drug. A 7-day treatment interval was used to avoid overlap. The pre-injection withdrawal threshold was checked to confirm the absence of the previous treatment.

Statistical analysis

Data are presented as mean ± standard deviation. The Statview 5.0 program (SAS Institute Inc., Cary, NC, USA) was used to test statistical significance. The withdrawal thresholds of each group were compared with a repeated-measures analysis of variance followed by Scheffe’s post hoc test. The demographic data and responses to the analgesic drugs were compared with the Mann-Whitney U and Wilcoxon signed-rank tests. A $P < 0.05$ was considered statistically significant.

Results

Rats showed normal gains in body weight during PAC or saline treatment. No significant difference in body weight was observed between the saline and PAC groups (Fig. 1). No significant difference was observed between the mechanical thresholds of the right and left hind paws. Data were calculated using the mean value obtained from both hind paws. The mechanical threshold decreased at PAC injection day 3 ($P < 0.05$) and was maintained to day 28 after the fourth PAC injection in the PAC treated group. No gender difference in the withdrawal threshold was observed in PAC-treated rats (Fig. 2).

An intraperitoneal injection of 2 mg/kg ketamine increased the mechanical threshold only in males (Fig. 3). However, no significant difference was observed between males and females. An intraperitoneal injection of 5 mg/kg ketamine increased the mechanical threshold in both genders. An intraperitoneal injection of 2 mg/kg or 5 mg/kg morphine increased the mechanical threshold in both genders dose dependently (Fig. 4). The combined use of 2 mg/kg morphine and 2 mg/kg ketamine
increased the mechanical threshold in both genders of rats (Fig. 5).

Maximal possible effects (MPE) were calculated as: MPE = 100 × (threshold post injection − threshold at baseline)/(15 − threshold at baseline). Morphine had dose-dependent analgesic effects in both genders. In contrast, ketamine showed a dose-dependent analgesic effect only in males. However, no significant difference was observed between males and females. The morphine and ketamine combination showed a statistically significant enhancement of the analgesic effect only in females, compared with individual injections of 2 mg/kg ketamine or 2 mg/kg morphine (Table 1).

Discussion

In this PAC-induced neuropathic pain model, the mechanical threshold decreased on the day of the third PAC injection and was maintained until the end of the experiment. No gender difference was observed for the withdrawal threshold in PAC-treated rats. The PINP mechanism has not been revealed, and there are no validated drugs for prevention and treatment. Several experimental animal models of chemotherapy-related neurotoxicity have been developed to reveal the mechanism. The present study was conducted using the PAC model of Polomano et al. [2]. Some authors have suggested that chemotherapy-induced painful neuropathy is accompanied by ultrastructural changes in unmyelinated sensory neurons, including cytoskeletal disorganization and microtubule disorientation. One study indicated that the pain is associated with dysfunction in Aβ, Aδ, and C-caliber primary afferent fibers [9]. Massive axonal degeneration occurs in post-traumatic painful peripheral neuropathy models, whereas animals with PINP have no axonal degeneration at the level of the peripheral
nerve [10,11]. PAC-treated rats have pronounced mechanical allodynia, cold allodynia, and mechanical hyperalgesia, but little or no heat hyperalgesia [2]. The nerve trauma models, such as the chronic constrictive injury model, produce the same symptoms but also produce pronounced heat hyperalgesia. Different mechanisms suggest the possibility of different pain responses and pharmacological response profiles.

Women are more likely than men to report acute and chronic pain [12] and use pain relieving medication significantly more often, even when pain frequency and severity is equaled between the genders [13]. Biological, cultural, psychological, and social factors are all hypothesized to contribute to these disparities in pain responses, reporting, and management [7]. In animals, most studies of gender differences in pain have examined acute nociception. In the partial nerve injury model, female rats are more susceptible to develop spread mechanical hypersensitivity, particularly after a facial nerve injury, compared with male rats. However, hypersensitivity of the hind paws after a sciatic nerve injury does not significantly differ between female and male rats [14], suggesting that gender differences in the neuropathic pain in rats depend on the site of injury and the type of test.

In this study, an intraperitoneal injection of 2 mg/kg or 5 mg/kg of morphine increased the mechanical threshold in both genders dose dependently. Opioid analgesic drugs are widely used for chronic pain, and morphine produces greater analgesia in males compared to that in female rats [15]. Three opioid receptors, μ, κ, and δ, are significantly implicated in modulating pain [16]. The μ receptor is the most clinically relevant receptor, as morphine and most other opioid agonists act preferentially at that site; thus, studies have focused most attention on this opioid receptor. In animal studies, the intensity of noxious stimulation used during pain testing influences the observed gender effect. Female predominance of μ-opioid analgesia is most notable at low to moderate intensities in thermal studies [17]. However, no significant difference in the anti-allodynic effect of morphine between male and female rats was observed in this study.

Cata et al. [18] reported that PINP in rats is accompanied by changes in sensory processing by spinal cord neurons as evidenced by increased spontaneous activity, which is prolonged after discharges due to natural mechanical and thermal stimuli and increased windup to cutaneous electrical stimuli. Similar changes are observed in rats with vincristine-induced painful neuropathy [10], chronic constriction neuropathy, and partial nerve injury neuropathy [19], as well as in several models of central sensitization. Increased spontaneous activity in dorsal horn neurons has been hypothesized to result from increased discharge in peripheral neuromas or pathophysiological dorsal root ganglia neurons due to denervation supersensitivity, disinhibition, synaptic reorganization, post-synaptic activation of N-methyl-D-aspartate (NMDA) receptors, and cyclooxygenase type-2 induction [20]. An NMDA antagonist would be helpful to diminish after-discharge in the wide dynamic range neurons. In general, low dose ketamine does not produce an analgesic effect [21]. A maximally tolerated dose of MK-801 results in incomplete reversal of mechanical allodynia in PINP [22]. However, low dose ketamine (2 mg/kg) showed an analgesic effect in male rats in the present study. In females, 5 mg/kg ketamine resulted in a notable increase in the withdrawal threshold compared to that of 2 mg/kg ketamine, suggesting that NMDA activation may be related to gender and the mechanism of neuropathic pain.

It has been established that the glutamate system interacts

Table 1. Maximal Possible Effects of Ketamine, Morphine, or Combined Use of Ketamine and Morphine on Paclitaxel-Induced Neuropathic Pain in Rats

| Treatment | Male | Female |
|-----------|------|--------|
| Ketamine 2 mg/kg i.p. | 19.9 ± 23.4 | 7.1 ± 6.5 |
| Ketamine 5 mg/kg i.p. | 46.6 ± 40.7 | 23.4 ± 21.1 |
| Morphine 2 mg/kg i.p. | 27.9 ± 30.3 | 21.6 ± 22.7 |
| Morphine 5 mg/kg i.p. | 85.8 ± 27.3 | 73.2 ± 34.7 |
| Ketamine 2 mg/kg + Morphine 2 mg/kg i.p. | 28.4 ± 37.4 | 56.1 ± 43.1*† |

No statistically significant difference was observed between males and females. A dose dependent increase in maximal possible effects occurred after the morphine injection in both genders. Ketamine (2 mg/kg) enhanced the analgesic effect of morphine only in females. MPE (%): Maximal possible effect = 100 × (threshold of post injection − threshold of baseline) / (15 − threshold of baseline), K2: 2 mg/kg ketamine, K5: 5 mg/kg ketamine, M2: 2 mg/kg morphine, M5: 5 mg/kg morphine, MK2: 2 mg/kg morphine and 2 mg/kg ketamine at the same time, *P < 0.05 compared to a 2 mg/kg injection of ketamine, †P < 0.05 compared to a 2 mg/kg injection of morphine.
with the opioid system. Opioids affect NMDA receptors, and NMDA receptors are involved in the development of opioid tolerance [23]. NMDA antagonists may potentiate opioid analgesia while preventing or slowing the development of opioid tolerance and dependence [24]. However, reports of NMDA antagonist modulation on the acute analgesic effects of opioid agonists vary from enhancement, to no effect, to attenuation [25-27]. In this study, 2 mg/kg ketamine enhanced the antinoceptive effect of 2 mg/kg morphine only in females. Some controversies exist as to the gender differences in the modulation of NMDA antagonists. Dextromethorphan enhances morphine analgesia in males but attenuates it in female rats [28]. In an acute pain model, there is enhancement of morphine antinociception by NMDA antagonist in both genders, but no effect is observed in females in a chronic pain model [29]. However, ketamine (3 mg/kg) produces a threefold increase in morphine (3 mg/kg) analgesia in female rats, whereas increase in morphine analgesia is negligible in male rats [21], which corresponds with the present study. These gender differences in the NMDA-opioid interaction are influenced by differences in neuroendocrine physiology, neurotransmitter density, and the physiological response to steroids [15,21]. The hippocampus of male rats contains significantly more AMPA, kainate, and NMDA receptors than those of female rats. Female rats in diestrus have significantly higher AMPA receptor densities than female rats in estrus [30]. These conflicting data show that morphine potentiation by NMDA antagonists follows a complex mechanism that may depend on the antinoceptive assay used, the pain model, and other factors such as type of antagonist, dose, and gender.

The effect of chemotherapy on body weight varies based on the type of agent and administered dose. A volume of data indicates that chemotherapy-treated rats fail to gain weight during the treatment period [10,11]. However, no significant change was observed between the normal saline group and the PAC-injected group in the current study. Rats treated with PAC (2 mg/kg, days 1, 3, 5, 7) gained weight normally. The PAC dose was selected in a range that would induce neuropathic pain without other complications.

The present study did not include any information about the effect of the estrous cycle or gonadal hormones. Therefore, more studies are required to understand the exact mechanism and other factors. Further research to obtain more information about gender differences of other therapeutic drugs may aid in the development of better treatment for PINP.

In summary, no difference in the incidence or severity of PINP was observed between male and female rats. No significant difference was observed in the analgesic effects of morphine or ketamine on the PINP. Low dose ketamine (2 mg/kg i.p.) alone was not effective for increasing the withdrawal threshold in females. However, a notable enhancement of the analgesic effect was shown when administered in combination with morphine in females. The results suggest that ketamine may play a significant role in the treatment of PINP when combined with opioids, particularly in females.

References

1. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981; 256: 10435-41.
2. Polomano RC, Mannes AJ, Clark US, Bennet GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001; 94: 293-304.
3. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003; 98: 822-31.
4. Tanner KD, Levine JD, Topp KS. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998; 395: 481-92.
5. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122: 245-57.
6. Kim MH, Lee JK. Ultrastructural changes of nerve fibers using a neuropathic pain model in a rat. Korean J Anesthesiol 2000; 38: 742-52.
7. Riley JL, 3rd, Robinson ME, Wise EA, Myers CD, Fillingim RB. Sex differences in the perception of noxious experimental stimuli: a meta-analysis. Pain 1998; 74: 181-7.
8. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980; 20: 441-62.
9. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage 2007; 33: 166-79.
10. Weng HR, Cordella JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 2003; 103: 131-8.
11. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 1998; 9: 443-7.
12. Unruh AM. Gender variations in clinical pain experience. Pain 1996; 65: 123-67.
13. Isacson D, Bingefors K. Epidemiology of analgesic use: a gender perspective. Eur J Anaesthesiol Suppl 2002; 26: 5-15.
14. Dominiguez CA, Kouya PF, Wu WP, Hao JX, Xu XJ, Wiesenfeld-Hallin Z. Sex differences in the development of localized and spread mechanical hypersensitivity in rats after injury to the infraorbital or sciatic nerves to create a model for neuropathic pain. Gend Med 2009; 6 Suppl 2: 225-34.
15. Craft RM. Sex differences in drug and non drug induced analgesia. Life Sci 2003; 72: 2675-88.
16. Przewlocki R, Przewlocka B. Opioids in chronic pain. Eur J Pharmacol 2001; 429: 79-91.
17. Negus SS, Zuzga DS, Mello NK. Sex differences in opioid antinociception in rhesus monkeys: Antagonism of fentanyl and U50,488 by quadazocine. J Pain 2002; 3: 218-26.

18. Cata JP, Weng HR, Chen JH, Dougherty PM. Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 2006; 138: 329-38.

19. Sotgiu ML, Biella G. Contribution of central sensitization to the pain-related abnormal activity in neuropathic rats. Somatosens Motor Res 2000; 17: 32-8.

20. DeVor M, Wall PD. Plasticity in the spinal cord sensory map following peripheral nerve injury in rats. J Neurosci 1981; 1: 679-84.

21. Holtman JR Jr, Jing X, Wala EP. Sex-related differences in the enhancement of morphine antinociception by NMDA receptor antagonists in rats. Pharmacol Biochem Behav 2003; 76: 285-93.

22. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004; 109: 150-61.

23. Bell RF. Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 1999; 83: 101-3.

24. Bisaga A, Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend 2000; 59: 1-15.

25. Caruso FS. MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain. J Pain Symptom Manage 2000; 19(Suppl): S31-6.

26. Heiskanen T, Härtel B, Dahl ML, Seppälä T, Kalso E. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 2002; 96: 261-7.

27. Hoffman VL, Vermeyen KM, Adriaensen HF, Meert TF. Effects of NMDA receptor antagonists on opioid-induced respiratory depression and acute antinociception in rats. Pharmacol Biochem Behav 2003; 74: 933-41.

28. Grisel JE, Allen S, Nemmani KV, Fee JR, Carliss R. The influence of dextromethorphan on morphine analgesia in Swiss Webster mice in sex-specific. Pharmacol Biochem Behav 2005; 81: 131-8.

29. Lomas LM, Terner JM, Picker MJ. Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain. Pharmacol Biochem Behav 2008; 89: 127-36.

30. Palomero-Gallagher N, Bidmon HJ, Zilles K. AMPA, kainate, and NMDA receptor densities in the hippocampus of untreated male rats and females in estrus and diestrus. J Comp Neurol 2003; 459: 468-74.